THC/CBD spray improved quality of life in a patient with stiff-person syndrome
A patient with stiff-person syndrome who had not responded to standard treatments showed improvement across all quality of life dimensions after 14 months of THC/CBD oral spray.
Quick Facts
What This Study Found
A 40-year-old man with seronegative stiff-person syndrome (SPS), a rare disorder causing progressive muscle rigidity and painful spasms, had not responded adequately to standard treatments. After starting THC/CBD oromucosal spray (Sativex), he showed improvement across all eight dimensions of the SF-36 quality of life questionnaire at the 14-month follow-up.
SPS is diagnosed based on clinical features and continuous motor unit activity on electrophysiology testing. This patient tested negative for glutamic acid decarboxylase (GAD) antibodies in both blood and cerebrospinal fluid, classifying him as seronegative.
Key Numbers
One patient, age 40, with six years of symptoms. Treatment duration was 14 months. Improvement was documented across all eight SF-36 quality of life dimensions.
How They Did This
Single case report describing a 40-year-old male with a six-year history of progressive muscle stiffness and intermittent spasms. After multiple unsuccessful standard treatments, THC/CBD oromucosal spray was introduced. Quality of life was assessed using the SF-36 questionnaire at baseline and after 14 months of treatment.
Why This Research Matters
Stiff-person syndrome is rare and difficult to treat. When standard therapies fail, clinicians have limited options. This case report documented a potential role for cannabinoid-based therapy in managing SPS symptoms, though it represents only a single patient experience.
The Bigger Picture
Both multiple sclerosis and stiff-person syndrome involve spasticity and rigidity. Since THC/CBD spray was already approved for MS-related spasticity in some countries, this case suggested the benefits might extend to other conditions with similar neurological symptoms.
What This Study Doesn't Tell Us
This is a single case report with no control comparison. Placebo effects, natural disease fluctuation, and concurrent treatments could all contribute to the observed improvement. SF-36 is a subjective quality of life measure. The findings cannot be generalized without controlled trials.
Questions This Raises
- ?Would controlled trials of THC/CBD spray in SPS patients confirm these results?
- ?Does the seronegative subtype of SPS respond differently to cannabinoid therapy than GAD-positive SPS?
- ?What is the mechanism by which cannabinoids might affect muscle rigidity in SPS?
Trust & Context
- Key Stat:
- Improvement across all 8 quality of life dimensions after 14 months of treatment
- Evidence Grade:
- Single case report. Interesting but cannot establish efficacy without controlled trials.
- Study Age:
- Published in 2013. Stiff-person syndrome remains rare, and controlled trials of cannabinoid therapy for SPS are limited.
- Original Title:
- Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
- Published In:
- Journal of clinical pharmacy and therapeutics, 38(1), 71-3 (2013)
- Authors:
- Vicente-Valor, M I, Garcia-Llopis, P, Mejia Andujar, L, Antonino de la Camara, G, García del Busto, N, Lopez Tinoco, M J, Quintana Vergara, B, Peiro Vilaplana, C, Dominguez Moran, J A, Sánchez Alcaraz, A
- Database ID:
- RTHC-00752
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is stiff-person syndrome?
A rare neurological disorder causing progressive muscle rigidity and painful spasms, typically involving the trunk and limbs. It is often treated with benzodiazepines, baclofen, and immunosuppressants.
Can cannabis treat stiff-person syndrome?
This single case report showed improvement with THC/CBD spray, but one patient does not constitute evidence of efficacy. Controlled trials would be needed to determine whether this approach works reliably.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00752APA
Vicente-Valor, M I; Garcia-Llopis, P; Mejia Andujar, L; Antonino de la Camara, G; García del Busto, N; Lopez Tinoco, M J; Quintana Vergara, B; Peiro Vilaplana, C; Dominguez Moran, J A; Sánchez Alcaraz, A. (2013). Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.. Journal of clinical pharmacy and therapeutics, 38(1), 71-3. https://doi.org/10.1111/j.1365-2710.2012.01365.x
MLA
Vicente-Valor, M I, et al. "Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.." Journal of clinical pharmacy and therapeutics, 2013. https://doi.org/10.1111/j.1365-2710.2012.01365.x
RethinkTHC
RethinkTHC Research Database. "Cannabis derivatives therapy for a seronegative stiff-person..." RTHC-00752. Retrieved from https://rethinkthc.com/research/vicente-valor-2013-cannabis-derivatives-therapy-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.